Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Nrc Health (NRC) EBITDA (2016 - 2026)

Nrc Health's EBITDA history spans 16 years, with the latest figure at $4.7 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 124.91% to $4.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $22.6 million, a 229.12% increase, with the full-year FY2025 number at $22.6 million, up 229.06% from a year prior.
  • EBITDA hit $4.7 million in Q4 2025 for Nrc Health, down from $7.7 million in the prior quarter.
  • Over the last five years, EBITDA for NRC hit a ceiling of $13.1 million in Q3 2021 and a floor of -$18.7 million in Q4 2024.
  • Historically, EBITDA has averaged $8.3 million across 5 years, with a median of $9.7 million in 2023.
  • Biggest five-year swings in EBITDA: crashed 260.06% in 2024 and later skyrocketed 124.91% in 2025.
  • Tracing NRC's EBITDA over 5 years: stood at $12.9 million in 2021, then decreased by 4.91% to $12.2 million in 2022, then decreased by 4.35% to $11.7 million in 2023, then crashed by 260.06% to -$18.7 million in 2024, then skyrocketed by 124.91% to $4.7 million in 2025.
  • Business Quant data shows EBITDA for NRC at $4.7 million in Q4 2025, $7.7 million in Q3 2025, and $1.6 million in Q2 2025.